{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:23:22Z","timestamp":1745468602730,"version":"3.40.4"},"reference-count":22,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ocul Oncol Pathol"],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;\/i&gt;&lt;\/b&gt; Stereotactic radiotherapy (SRT) is used for choroidal melanoma (CM) abutting the optic nerve. Visual acuity (VA) deterioration to \u22646\/60 is common. We report a pilot study of reduced-dose SRT using 2 Gy\/day, aiming to preserve vision without compromising survival. &lt;b&gt;&lt;i&gt;Method:&lt;\/i&gt;&lt;\/b&gt; 60 Gy SRT was delivered in 30 fractions over 6 weeks. Liver metastasis surveillance was annual ultrasound. The primary endpoint was 5-year metastasis-free survival (5yMFS). Secondary endpoints were 2-year freedom from local progression (2yFFLP), VA, enucleation rate, and radiation toxicity. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Twenty adults aged \u226470 years with T1-T2M0 CM without diabetes mellitus were enrolled. Median follow-up was 5.1 years. About 85% and 90% of tumours were \u22643 mm of the macula and optic disc, respectively. Median tumour height was 2.2 mm (range 1.0\u20134.4 mm), and median basal diameter was 8.2 mm (range: 4.3\u201315.0 mm). 5yMFS was 88% (95% CI: 61\u201397), and the 2yFFLP rate was 90% (95%: CI 66\u201397). There were three enucleations for disease progression. Final VA in retained eyes was \u22656\/7.5 in 6 (30%), 6\/9 to 6\/12 in 5 (25%), 6\/15 to 6\/48 in 2 (10%), and \u22646\/60 in 4 (20%) eyes. Retinopathy was the main cause of vision loss besides tumour progression. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; Meaningful vision was preserved 5 years after SRT, despite high-risk tumour locations for vision loss. 2yFFLP and 5yMFS were acceptable. This dose fractionation warrants further investigation. <\/jats:p>","DOI":"10.1159\/000538022","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T22:00:43Z","timestamp":1711576843000},"page":"72-79","source":"Crossref","is-referenced-by-count":0,"title":["Is It Possible to Preserve Vision without Compromising Metastases-Free Survival by Use of Fully Fractionated Stereotactic Radiotherapy for Posterior Choroidal Melanoma?"],"prefix":"10.1159","volume":"10","author":[{"given":"Claire E.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkan","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rod","family":"O'Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Sia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"McKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred Kuanfu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302490"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1820572"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00062-4"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.6.773"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.08.018"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/radonc.2012.10.006"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s13246-017-0551-5"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjopt.2013.06.014"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2015.02.008"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2015.02.008"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.10.077"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.08.059"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.03.019"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.014"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.02.022"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.12.1684"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(02)01277-0"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.000000000000"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000520218"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021025529-z"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.03.010"}],"container-title":["Ocular Oncology and Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/oop\/article-pdf\/10\/2\/72\/4242098\/000538022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/oop\/article-pdf\/10\/2\/72\/4242098\/000538022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:09:08Z","timestamp":1745420948000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000538022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,6,14]]},"published-print":{"date-parts":[[2024,6,19]]}},"URL":"https:\/\/doi.org\/10.1159\/000538022","archive":["Portico"],"relation":{},"ISSN":["2296-4681","2296-4657"],"issn-type":[{"type":"print","value":"2296-4681"},{"type":"electronic","value":"2296-4657"}],"subject":[],"published":{"date-parts":[[2024]]}}}